Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B | P35368 | 10/20 | 0.52 |
| ▸ | HTR1A | P08908 | 10/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334544 | 0.92 | SMN1; SMN2 (0.50) | ADRA1BHTR1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4324667 | 0.92 | SMN1; SMN2 (0.53) | ADRA1BHTR1ASMN1; SMN2ADRA1AADRA1D | |
| SCHEMBL4332484 | 0.90 | SMN1; SMN2 (0.56) | ADRA1BHTR1ASMN1; SMN2ADRA1AADRA1D | |
| SCHEMBL4331760 | 0.89 | ADRA1D (0.55) | ADRA1BHTR1AADRA1AADRA1D | |
| SCHEMBL4332839 | 0.88 | HTR1A (0.55) | HTR1AALDH1A1 | |
| SCHEMBL4326325 | 0.88 | ADRA1D (0.50) | ADRA1BHTR1ASMN1; SMN2ADRA1AADRA1D | |
| SCHEMBL4334356 | 0.87 | KDM4E (0.52) | ADRA1BHTR1ASMN1; SMN2ADRA1AADRA1D | |
| SCHEMBL4325798 | 0.86 | DRD4 (0.56) | HTR1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4320070 | 0.86 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL8259509 | 0.85 | ALDH1A1 (0.52) | ADRA1BHTR1ASMN1; SMN2ADRA1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | ADRA1B 224/4885HTR1A 38/4885SMN1; SMN2 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.